The hypothalamus and brainstem circuits that govern sleep-wake transitions are among the most inflammation-sensitive in the brain. Neuroinflammation — driven by microglial activation and elevated inflammatory cytokines — disrupts these circuits, impairing the precise regulation of sleep onset, sleep depth, and circadian timing. HBOT's documented anti-neuroinflammatory effects, including reductions in microglial activation and pro-inflammatory signaling, may directly improve the function of sleep-regulating brain circuits.

Deep sleep — particularly slow-wave sleep — is metabolically demanding for the brain. It requires sustained energy production and adequate oxygen delivery to support the neural processes of memory consolidation, cellular repair, and glymphatic waste clearance. When cerebral oxygenation is chronically reduced — whether from sleep apnea, vascular insufficiency, or other causes — sleep architecture suffers. HBOT delivers 10x normal tissue oxygen concentration, and researchers are investigating whether this oxygen restoration improves the depth and architecture of sleep.

The glymphatic system — the brain's lymphatic-like waste-clearance network — operates primarily during deep sleep, using cerebrospinal fluid to flush metabolic waste products including amyloid-beta and tau proteins from brain tissue. Disrupted sleep impairs glymphatic function; impaired glymphatic function further disrupts sleep quality in a self-reinforcing cycle. Improved sleep depth following HBOT may support glymphatic clearance — and improved brain health from reduced metabolic waste accumulation may in turn further improve sleep.

Chronic pain, PTSD, anxiety, Long COVID, and fibromyalgia are among the most common secondary drivers of sleep disruption — and HBOT has documented effects on all of them. Sleep improvements in HBOT research are frequently observed as secondary outcomes in studies targeting these primary conditions, suggesting that when HBOT reduces the pain, hyperarousal, or systemic inflammation driving poor sleep, sleep quality improves as a downstream effect. For patients with sleep disruption driven by comorbid conditions, this indirect pathway may be clinically significant.

Hypoxia-inducible factor 1-alpha (HIF-1α) is a key molecular regulator that is activated under both hypoxic and hyperoxic conditions — including HBOT. Emerging research is exploring the relationship between HIF-1α signaling and circadian clock genes, suggesting that HBOT may influence the molecular machinery of circadian biology in ways that could support sleep-wake timing. This is early-stage research, but it represents a potentially direct cellular mechanism connecting HBOT to the regulation of sleep architecture beyond anti-inflammatory effects.

A key finding from Hadanny et al. (2024) is that improvements following HBOT — including sleep quality — persist for over a year after the treatment protocol ends. This durability suggests structural or functional neurological changes rather than a temporary symptomatic effect. If HBOT produces lasting improvements in neuroinflammatory burden, cerebral oxygenation, or sleep-regulating circuit function, the sleep benefits may be durable — representing a meaningful shift in the biological conditions that govern sleep rather than a short-term intervention effect.